{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:14:42Z","timestamp":1791090882005,"version":"4.1.0"},"reference-count":183,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cardiovasc Imaging"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hypertrophic cardiomyopathy (HCM) is a disease characterized by unexplained left ventricular hypertrophy and is caused by mutations in cardiac sarcomeric proteins. Despite advances in diagnostic modalities and risk stratification, therapeutic strategies have until recently mostly focused on the management of symptoms and the prevention of sudden cardiac death, rather than modifying the underlying sarcomeric dysfunction itself. Conventional pharmacological therapies such as \u03b2-blockers and nondihydropyridine calcium channel blockers are effective first-line treatments for obstructive HCM, and established invasive septal reduction therapies, such as surgical myectomy and alcohol septal ablation, provide effective relief of obstruction in refractory patients. However, these therapies address anatomical and hemodynamical consequences rather than the molecular etiology of the disease. In recent years, novel therapeutic approaches have emerged that target the pathophysiological mechanisms of HCM more directly. Sodium-glucose cotransporter 2 inhibitors have demonstrated clinical benefits in HCM through improvements in myocardial energetics. Cardiac myosin inhibitors directly attenuate sarcomeric hypercontractility and have shown improvements in symptoms, functional status, and hemodynamic parameters in obstructive HCM. Furthermore, preliminary gene-targeted therapies are under active investigation and offer the prospect of definitive cure. This review provides a comprehensive overview of current and emerging treatment modalities for HCM. Overall, the management of HCM is evolving toward a more mechanism-targeted approach spanning from gene to myocardium. Ongoing research will be essential to integrate the emerging molecularly targeted therapies with established management strategies into a personalized, multidisciplinary management of HCM.<\/jats:p>","DOI":"10.1186\/s44348-025-00050-9","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T08:46:59Z","timestamp":1758703619000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Current and emerging medical and surgical therapy in hypertrophic cardiomyopathy"],"prefix":"10.1186","volume":"33","author":[{"given":"Kyung An","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi-Hyang","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"key":"50_CR1","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1161\/01.CIR.92.4.785","volume":"92","author":"BJ Maron","year":"1995","unstructured":"Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA Study Coronary Artery Risk Development in (Young) Adults. Circulation. 1995;92:785\u20139.","journal-title":"Circulation."},{"key":"50_CR2","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0002-9149(87)80107-8","volume":"59","author":"Y Hada","year":"1987","unstructured":"Hada Y, Sakamoto T, Amano K, Yamaguchi T, Takenaka K, Takahashi H, et al. Prevalence of hypertrophic cardiomyopathy in a population of adult Japanese workers as detected by echocardiographic screening. Am J Cardiol. 1987;59:183\u20134.","journal-title":"Am J Cardiol"},{"key":"50_CR3","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.jchf.2018.03.004","volume":"6","author":"BJ Maron","year":"2018","unstructured":"Maron BJ, Rowin EJ, Maron MS. Global burden of hypertrophic cardiomyopathy. JACC Heart Fail. 2018;6:376\u20138.","journal-title":"JACC Heart Fail"},{"key":"50_CR4","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","volume":"44","author":"E Arbelo","year":"2023","unstructured":"Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44:3503\u2013626.","journal-title":"Eur Heart J"},{"key":"50_CR5","doi-asserted-by":"publisher","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","volume":"149","author":"SR Ommen","year":"2024","unstructured":"Ommen SR, Ho CY, Asif IM, Balaji S, Burke MA, Day SM, et al. 2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR Guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149:e1239\u2013311.","journal-title":"Circulation"},{"key":"50_CR6","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1161\/CIRCRESAHA.121.318346","volume":"128","author":"AJ Marian","year":"2021","unstructured":"Marian AJ. Molecular genetic basis of hypertrophic cardiomyopathy. Circ Res. 2021;128:1533\u201353.","journal-title":"Circ Res"},{"key":"50_CR7","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1161\/hc4601.097997","volume":"104","author":"I Olivotto","year":"2001","unstructured":"Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation. 2001;104:2517\u201324.","journal-title":"Circulation"},{"key":"50_CR8","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","volume":"114","author":"MS Maron","year":"2006","unstructured":"Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 2006;114:2232\u20139.","journal-title":"Circulation"},{"key":"50_CR9","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1136\/heartjnl-2016-310720","volume":"103","author":"SE Lee","year":"2017","unstructured":"Lee SE, Park JK, Uhm JS, Kim JY, Pak HN, Lee MH, et al. Impact of atrial fibrillation on the clinical course of apical hypertrophic cardiomyopathy. Heart. 2017;103:1496\u2013501.","journal-title":"Heart"},{"key":"50_CR10","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1093\/eurheartj\/ehs150","volume":"33","author":"R Spoladore","year":"2012","unstructured":"Spoladore R, Maron MS, D\u2019Amato R, Camici PG, Olivotto I. Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence. Eur Heart J. 2012;33:1724\u201333.","journal-title":"Eur Heart J"},{"key":"50_CR11","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/cvr\/cvv023","volume":"105","author":"JC Tardiff","year":"2015","unstructured":"Tardiff JC, Carrier L, Bers DM, Poggesi C, Ferrantini C, Coppini R, et al. Targets for therapy in sarcomeric cardiomyopathies. Cardiovasc Res. 2015;105:457\u201370.","journal-title":"Cardiovasc Res"},{"key":"50_CR12","doi-asserted-by":"publisher","unstructured":"Jung MH, Cho JS, Lee SY, Youn JC, Choi Y, Chung WB, et al. Sodium-glucose cotransporter-2 inhibitors and clinical outcomes in patients with hypertrophic cardiomyopathy and diabetes: a population-based cohort study. Eur J Prev Cardiol. 2024. https:\/\/doi.org\/10.1093\/eurjpc\/zwae345.","DOI":"10.1093\/eurjpc\/zwae345"},{"key":"50_CR13","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","volume":"396","author":"I Olivotto","year":"2020","unstructured":"Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396:759\u201369.","journal-title":"Lancet"},{"key":"50_CR14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","volume":"80","author":"MY Desai","year":"2022","unstructured":"Desai MY, Owens A, Geske JB, Wolski K, Naidu SS, Smedira NG, et al. Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy. J Am Coll Cardiol. 2022;80:95\u2013108.","journal-title":"J Am Coll Cardiol"},{"key":"50_CR15","doi-asserted-by":"publisher","first-page":"339","DOI":"10.4070\/kcj.2024.0443","volume":"55","author":"J Lim","year":"2025","unstructured":"Lim J, Cho JY, Kwak S, Park CS, Park J, Choi HM, et al. Real-world experience of mavacamten for patients with obstructive hypertrophic cardiomyopathy in South Korea: a prospective multi-center observational study. Korean Circ J. 2025;55:339\u201354.","journal-title":"Korean Circ J"},{"key":"50_CR16","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s41591-022-02176-5","volume":"29","author":"AC Chai","year":"2023","unstructured":"Chai AC, Cui M, Chemello F, Li H, Chen K, Tan W, et al. Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes and humanized mice. Nat Med. 2023;29:401\u201311.","journal-title":"Nat Med"},{"key":"50_CR17","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41591-022-02190-7","volume":"29","author":"D Reichart","year":"2023","unstructured":"Reichart D, Newby GA, Wakimoto H, Lun M, Gorham JM, Curran JJ, et al. Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice. Nat Med. 2023;29:412\u201321.","journal-title":"Nat Med"},{"key":"50_CR18","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1093\/cvr\/cvae107","volume":"120","author":"MY Desai","year":"2024","unstructured":"Desai MY. The promise of gene therapy in hypertrophic cardiomyopathy: emergence of human experience. Cardiovasc Res. 2024;120:e33\u20135.","journal-title":"Cardiovasc Res"},{"key":"50_CR19","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1161\/01.CIR.35.5.847","volume":"35","author":"LS Cohen","year":"1967","unstructured":"Cohen LS, Braunwald E. Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade. Circulation. 1967;35:847\u201351.","journal-title":"Circulation"},{"key":"50_CR20","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.jacc.2022.02.021","volume":"79","author":"BA Borlaug","year":"2022","unstructured":"Borlaug BA, Omote K. Beta-blockers and exercise hemodynamics in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2022;79:1576\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"50_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2023.100622","volume":"2","author":"M Zhu","year":"2023","unstructured":"Zhu M, Reyes KR, Bilgili G, Siegel RJ, Lee Claggett B, Wong TC, et al. Medical therapies to improve left ventricular outflow obstruction and diastolic function in hypertrophic cardiomyopathy. JACC Adv. 2023;2: 100622.","journal-title":"JACC Adv"},{"key":"50_CR22","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1161\/01.CIR.38.5.846","volume":"38","author":"MD Flamm","year":"1968","unstructured":"Flamm MD, Harrison DC, Hancock EW. Muscular subaortic stenosis: prevention of outflow obstruction with propranolol. Circulation. 1968;38:846\u201358.","journal-title":"Circulation"},{"key":"50_CR23","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1136\/hrt.32.6.804","volume":"32","author":"AG Adelman","year":"1970","unstructured":"Adelman AG, Shah PM, Gramiak R, Wigle ED. Long-term propranolol therapy in muscular subaortic stenosis. Br Heart J. 1970;32:804\u201311.","journal-title":"Br Heart J"},{"key":"50_CR24","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/0002-9149(73)90012-X","volume":"31","author":"RE Stenson","year":"1973","unstructured":"Stenson RE, Flamm MD Jr, Harrison DC, Hancock EW. Hypertrophic subaortic stenosis: clinical and hemodynamic effects of long-term propranolol therapy. Am J Cardiol. 1973;31:763\u201373.","journal-title":"Am J Cardiol"},{"key":"50_CR25","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1016\/S0735-1097(99)00421-0","volume":"34","author":"I Ostman-Smith","year":"1999","unstructured":"Ostman-Smith I, Wettrell G, Riesenfeld T. A cohort study of childhood hypertrophic cardiomyopathy: improved survival following high-dose beta-adrenoceptor antagonist treatment. J Am Coll Cardiol. 1999;34:1813\u201322.","journal-title":"J Am Coll Cardiol"},{"key":"50_CR26","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ijcard.2006.04.080","volume":"117","author":"F Cabrera-Bueno","year":"2007","unstructured":"Cabrera-Bueno F, Garc\u00eda-Pinilla JM, G\u00f3mez-Doblas JJ, Montiel-Trujillo A, Rodr\u00edguez-Bail\u00f3n I, de Teresa-Galv\u00e1n E. Beta-blocker therapy for dynamic left ventricular outflow tract obstruction induced by exercise. Int J Cardiol. 2007;117:222\u20136.","journal-title":"Int J Cardiol"},{"key":"50_CR27","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1016\/j.jacc.2021.07.065","volume":"78","author":"AM Dybro","year":"2021","unstructured":"Dybro AM, Rasmussen TB, Nielsen RR, Andersen MJ, Jensen MK, Poulsen SH. Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2021;78:2505\u201317.","journal-title":"J Am Coll Cardiol"},{"key":"50_CR28","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/j.jacc.2022.02.024","volume":"79","author":"AM Dybro","year":"2022","unstructured":"Dybro AM, Rasmussen TB, Nielsen RR, Ladefoged BT, Andersen MJ, Jensen MK, et al. Effects of metoprolol on exercise hemodynamics in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2022;79:1565\u201375.","journal-title":"J Am Coll Cardiol"},{"key":"50_CR29","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/ejhf.2737","volume":"25","author":"MT Wheeler","year":"2023","unstructured":"Wheeler MT, Jacoby D, Elliott PM, Saberi S, Hegde SM, Lakdawala NK, et al. Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy. Eur J Heart Fail. 2023;25:260\u201370.","journal-title":"Eur J Heart Fail"},{"key":"50_CR30","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1161\/01.CIR.64.4.787","volume":"64","author":"RO Bonow","year":"1981","unstructured":"Bonow RO, Rosing DR, Bacharach SL, Green MV, Kent KM, Lipson LC, et al. Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy. Circulation. 1981;64:787\u201396.","journal-title":"Circulation"},{"key":"50_CR31","first-page":"1201","volume":"60","author":"DR Rosing","year":"1979","unstructured":"Rosing DR, Kent KM, Borer JS, Seides SF, Maron BJ, Epstein SE. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I Hemodynamic effects Circulation. 1979;60:1201\u20137.","journal-title":"I Hemodynamic effects Circulation"},{"key":"50_CR32","doi-asserted-by":"crossref","unstructured":"Rosing DR, Kent KM, Maron BJ, Epstein SE. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status. Circulation. 1979;60:1208\u201313.","DOI":"10.1161\/01.CIR.60.6.1208"},{"key":"50_CR33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1136\/hrt.42.1.35","volume":"42","author":"M Kaltenbach","year":"1979","unstructured":"Kaltenbach M, Hopf R, Kober G, Bussmann WD, Keller M, Petersen Y. Treatment of hypertrophic obstructive cardiomyopathy with verapamil. Br Heart J. 1979;42:35\u201342.","journal-title":"Br Heart J"},{"key":"50_CR34","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1161\/01.CIR.79.5.1052","volume":"79","author":"JE Udelson","year":"1989","unstructured":"Udelson JE, Bonow RO, O\u2019Gara PT, Maron BJ, Van Lingen A, Bacharach SL, et al. Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy. Circulation. 1989;79:1052\u201360.","journal-title":"Circulation"},{"key":"50_CR35","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1161\/01.CIR.64.3.437","volume":"64","author":"SE Epstein","year":"1981","unstructured":"Epstein SE, Rosing DR. Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation. 1981;64:437\u201341.","journal-title":"Circulation"},{"key":"50_CR36","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1161\/01.CIR.81.2.593","volume":"81","author":"T Yamakado","year":"1990","unstructured":"Yamakado T, Okano H, Higashiyama S, Hamada M, Nakano T, Takezawa H. Effects of nifedipine on left ventricular diastolic function in patients with asymptomatic or minimally symptomatic hypertrophic cardiomyopathy. Circulation. 1990;81:593\u2013601.","journal-title":"Circulation"},{"key":"50_CR37","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S0735-1097(83)80235-6","volume":"2","author":"WJ Paulus","year":"1983","unstructured":"Paulus WJ, Lorell BH, Craig WE, Wynne J, Murgo JP, Grossman W. Comparison of the effects of nitroprusside and nifedipine on diastolic properties in patients with hypertrophic cardiomyopathy: altered left ventricular loading or improved muscle inactivation? J Am Coll Cardiol. 1983;2:879\u201386.","journal-title":"J Am Coll Cardiol"},{"key":"50_CR38","doi-asserted-by":"publisher","first-page":"606","DOI":"10.4070\/kcj.2023.0035","volume":"53","author":"CS Park","year":"2023","unstructured":"Park CS, Rhee TM, Lee HJ, Yoon YE, Park JB, Lee SP, et al. Prognostic and safety implications of renin-angiotensin-aldosterone system inhibitors in hypertrophic cardiomyopathy: a real-world observation over 2,000 patients. Korean Circ J. 2023;53:606\u201318.","journal-title":"Korean Circ J"},{"key":"50_CR39","doi-asserted-by":"publisher","first-page":"7","DOI":"10.5339\/gcsp.2015.7","volume":"2015","author":"I Olivotto","year":"2015","unstructured":"Olivotto I, Ashley EA. INHERIT (inhibition of the renin angiotensin system in hypertrophic cardiomyopathy and the effect on hypertrophy: a randomised intervention trial with losartan). Glob Cardiol Sci Pract. 2015;2015:7.","journal-title":"Glob Cardiol Sci Pract"},{"key":"50_CR40","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJM198210143071607","volume":"307","author":"C Pollick","year":"1982","unstructured":"Pollick C. Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide. N Engl J Med. 1982;307:997\u20139.","journal-title":"N Engl J Med"},{"key":"50_CR41","doi-asserted-by":"crossref","unstructured":"Pollick C, Kimball B, Henderson M, Wigle ED. Disopyramide in hypertrophic cardiomyopathy. I. Hemodynamic assessment after intravenous administration. Am J Cardiol. 1988;62:1248\u201351.","DOI":"10.1016\/0002-9149(88)90268-8"},{"key":"50_CR42","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1161\/01.CIR.66.2.447","volume":"66","author":"C Pollick","year":"1982","unstructured":"Pollick C, Giacomini KM, Blaschke TF, Nelson WL, Turner-Tamiyasu K, Briskin V, et al. The cardiac effects of d- and l-disopyramide in normal subjects: a noninvasive study. Circulation. 1982;66:447\u201353.","journal-title":"Circulation"},{"key":"50_CR43","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/0002-9149(88)90553-X","volume":"62","author":"M Sherrid","year":"1988","unstructured":"Sherrid M, Delia E, Dwyer E. Oral disopyramide therapy for obstructive hypertrophic cardiomyopathy. Am J Cardiol. 1988;62:1085\u20138.","journal-title":"Am J Cardiol"},{"key":"50_CR44","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.jacc.2005.01.012","volume":"45","author":"MV Sherrid","year":"2005","unstructured":"Sherrid MV, Barac I, McKenna WJ, Elliott PM, Dickie S, Chojnowska L, et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;45:1251\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"50_CR45","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1161\/CIRCHEARTFAILURE.112.000122","volume":"6","author":"MV Sherrid","year":"2013","unstructured":"Sherrid MV, Shetty A, Winson G, Kim B, Musat D, Alviar CL, et al. Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with \u03b2-blockade or verapamil. Circ Heart Fail. 2013;6:694\u2013702.","journal-title":"Circ Heart Fail"},{"key":"50_CR46","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.005152","volume":"6","author":"A Adler","year":"2017","unstructured":"Adler A, Fourey D, Weissler-Snir A, Hindieh W, Chan RH, Gollob MH, et al. Safety of outpatient initiation of disopyramide for obstructive hypertrophic cardiomyopathy patients. J Am Heart Assoc. 2017;6: e005152.","journal-title":"J Am Heart Assoc"},{"key":"50_CR47","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1161\/01.CIR.67.2.413","volume":"67","author":"RL Spicer","year":"1983","unstructured":"Spicer RL, Rocchini AP, Crowley DC, Vasiliades J, Rosenthal A. Hemodynamic effects of verapamil in children and adolescents with hypertrophic cardiomyopathy. Circulation. 1983;67:413\u201320.","journal-title":"Circulation"},{"key":"50_CR48","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/0002-8703(85)90357-6","volume":"109","author":"C Bourmayan","year":"1985","unstructured":"Bourmayan C, Razavi A, Fournier C, Dussaule JC, Baragan J, Gerbaux A, et al. Effect of propranolol on left ventricular relaxation in hypertrophic cardiomyopathy: an echographic study. Am Heart J. 1985;109:1311\u20136.","journal-title":"Am Heart J"},{"key":"50_CR49","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1136\/hrt.56.6.544","volume":"56","author":"PT Wilmshurst","year":"1986","unstructured":"Wilmshurst PT, Thompson DS, Juul SM, Jenkins BS, Webb-Peploe MM. Effects of verapamil on haemodynamic function and myocardial metabolism in patients with hypertrophic cardiomyopathy. Br Heart J. 1986;56:544\u201353.","journal-title":"Br Heart J"},{"key":"50_CR50","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1536\/ihj.27.701","volume":"27","author":"H Toshima","year":"1986","unstructured":"Toshima H, Koga Y, Nagata H, Toyomasu K, Itaya K, Matoba T. Comparable effects of oral diltiazem and verapamil in the treatment of hypertrophic cardiomyopathy: double-blind crossover study. Jpn Heart J. 1986;27:701\u201315.","journal-title":"Jpn Heart J"},{"key":"50_CR51","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/BF03164924","volume":"12","author":"H Sugihara","year":"1998","unstructured":"Sugihara H, Taniguchi Y, Ito K, Terada K, Matsumoto K, Kinoshita N, et al. Effects of diltiazem on myocardial perfusion abnormalities during exercise in patients with hypertrophic cardiomyopathy. Ann Nucl Med. 1998;12:349\u201354.","journal-title":"Ann Nucl Med"},{"key":"50_CR52","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/0735-1097(93)90386-F","volume":"21","author":"DM Gilligan","year":"1993","unstructured":"Gilligan DM, Chan WL, Joshi J, Clarke P, Fletcher A, Krikler S, et al. A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy. J Am Coll Cardiol. 1993;21:1672\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"50_CR53","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995\u20132008.","journal-title":"N Engl J Med"},{"key":"50_CR54","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413\u201324.","journal-title":"N Engl J Med"},{"key":"50_CR55","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451\u201361.","journal-title":"N Engl J Med"},{"key":"50_CR56","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJ, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387:1089\u201398.","journal-title":"N Engl J Med"},{"key":"50_CR57","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1093\/cvr\/cvae004","volume":"120","author":"PJ Wijnker","year":"2024","unstructured":"Wijnker PJ, Dinani R, van der Laan NC, Alg\u00fcl S, Knollmann BC, Verkerk AO, et al. Hypertrophic cardiomyopathy dysfunction mimicked in human engineered heart tissue and improved by sodium-glucose cotransporter 2 inhibitors. Cardiovasc Res. 2024;120:301\u201317.","journal-title":"Cardiovasc Res"},{"key":"50_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12997\/jla.2022.11.1.1","volume":"11","author":"H Saucedo-Orozco","year":"2022","unstructured":"Saucedo-Orozco H, Voorrips SN, Yurista SR, de Boer RA, Westenbrink BD. SGLT2 inhibitors and Ketone metabolism in heart failure. J Lipid Atheroscler. 2022;11:1\u201319.","journal-title":"J Lipid Atheroscler"},{"key":"50_CR59","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1093\/cvr\/cvad157","volume":"119","author":"D Chase","year":"2023","unstructured":"Chase D, Eykyn TR, Shattock MJ, Chung YJ. Empagliflozin improves cardiac energetics during ischaemia\/reperfusion by directly increasing cardiac ketone utilization. Cardiovasc Res. 2023;119:2672\u201380.","journal-title":"Cardiovasc Res"},{"key":"50_CR60","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1161\/CIRCULATIONAHA.121.053350","volume":"143","author":"K Philippaert","year":"2021","unstructured":"Philippaert K, Kalyaanamoorthy S, Fatehi M, Long W, Soni S, Byrne NJ, et al. Cardiac late sodium channel current is a molecular target for the sodium\/glucose cotransporter 2 inhibitor empagliflozin. Circulation. 2021;143:2188\u2013204.","journal-title":"Circulation"},{"key":"50_CR61","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","volume":"60","author":"A Baartscheer","year":"2017","unstructured":"Baartscheer A, Schumacher CA, W\u00fcst RC, Fiolet JW, Stienen GJ, Coronel R, et al. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+\/H+ exchanger in rats and rabbits. Diabetologia. 2017;60:568\u201373.","journal-title":"Diabetologia"},{"key":"50_CR62","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.amjcard.2022.10.054","volume":"188","author":"M Subramanian","year":"2023","unstructured":"Subramanian M, Sravani V, Krishna SP, Bijjam S, Sunehra C, Yalagudri S, et al. Efficacy of SGLT2 inhibitors in patients with diabetes and nonobstructive hypertrophic cardiomyopathy. Am J Cardiol. 2023;188:80\u20136.","journal-title":"Am J Cardiol"},{"key":"50_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2024.100843","volume":"3","author":"A Aglan","year":"2024","unstructured":"Aglan A, Fath AR, Eldaly AS, Anderson AS, Phillips JS, Maron BJ, et al. Impact of sodium-glucose cotransporter 2 inhibitors on mortality in hypertrophic cardiomyopathy. JACC Adv. 2024;3: 100843.","journal-title":"JACC Adv"},{"key":"50_CR64","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jacc.2022.10.020","volume":"81","author":"MS Maron","year":"2023","unstructured":"Maron MS, Masri A, Choudhury L, Olivotto I, Saberi S, Wang A, et al. Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2023;81:34\u201345.","journal-title":"J Am Coll Cardiol"},{"key":"50_CR65","doi-asserted-by":"publisher","first-page":"16571","DOI":"10.1074\/jbc.M117.776815","volume":"292","author":"RF Kawas","year":"2017","unstructured":"Kawas RF, Anderson RL, Ingle SR, Song Y, Sran AS, Rodriguez HM. A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle. J Biol Chem. 2017;292:16571\u20137.","journal-title":"J Biol Chem"},{"key":"50_CR66","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/s41591-022-02184-5","volume":"29","author":"A Strong","year":"2023","unstructured":"Strong A. CRISPR gene-editing therapies for hypertrophic cardiomyopathy. Nat Med. 2023;29:305\u20136.","journal-title":"Nat Med"},{"key":"50_CR67","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.gene.2015.09.008","volume":"573","author":"L Carrier","year":"2015","unstructured":"Carrier L, Mearini G, Stathopoulou K, Cuello F. Cardiac myosin-binding protein C (MYBPC3) in cardiac pathophysiology. Gene. 2015;573:188\u201397.","journal-title":"Gene"},{"key":"50_CR68","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1161\/CIRCULATIONAHA.108.838672","volume":"119","author":"SJ van Dijk","year":"2009","unstructured":"van Dijk SJ, Dooijes D, dos Remedios C, Michels M, Lamers JM, Winegrad S, et al. Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. Circulation. 2009;119:1473\u201383.","journal-title":"Circulation"},{"key":"50_CR69","doi-asserted-by":"publisher","first-page":"5515","DOI":"10.1038\/ncomms6515","volume":"5","author":"G Mearini","year":"2014","unstructured":"Mearini G, Stimpel D, Geertz B, Weinberger F, Kr\u00e4mer E, Schlossarek S, et al. Mybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in mice. Nat Commun. 2014;5:5515.","journal-title":"Nat Commun"},{"key":"50_CR70","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.130182","volume":"5","author":"J Li","year":"2020","unstructured":"Li J, Mamidi R, Doh CY, Holmes JB, Bharambe N, Ramachandran R, et al. AAV9 gene transfer of cMyBPC N-terminal domains ameliorates cardiomyopathy in cMyBPC-deficient mice. JCI Insight. 2020;5: e130182.","journal-title":"JCI Insight"},{"key":"50_CR71","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1161\/CIRCHEARTFAILURE.112.968941","volume":"5","author":"S Merkulov","year":"2012","unstructured":"Merkulov S, Chen X, Chandler MP, Stelzer JE. In vivo cardiac myosin binding protein C gene transfer rescues myofilament contractile dysfunction in cardiac myosin binding protein C null mice. Circ Heart Fail. 2012;5:635\u201344.","journal-title":"Circ Heart Fail"},{"key":"50_CR72","doi-asserted-by":"crossref","unstructured":"Monteiro da Rocha A, Guerrero-Serna G, Helms A, Luzod C, Mironov S, Russell M, et al. Deficient cMyBP-C protein expression during cardiomyocyte differentiation underlies human hypertrophic cardiomyopathy cellular phenotypes in disease specific human ES cell derived cardiomyocytes. J Mol Cell Cardiol. 2016;99:197\u2013206.","DOI":"10.1016\/j.yjmcc.2016.09.004"},{"key":"50_CR73","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.omtn.2017.05.008","volume":"7","author":"M Prondzynski","year":"2017","unstructured":"Prondzynski M, Kr\u00e4mer E, Laufer SD, Shibamiya A, Pless O, Flenner F, et al. Evaluation of MYBPC3 trans-splicing and gene replacement as therapeutic options in human iPSC-derived cardiomyocytes. Mol Ther Nucleic Acids. 2017;7:475\u201386.","journal-title":"Mol Ther Nucleic Acids"},{"key":"50_CR74","doi-asserted-by":"publisher","first-page":"37","DOI":"10.12997\/jla.2023.12.1.37","volume":"12","author":"KA Kim","year":"2023","unstructured":"Kim KA, Park HJ. New therapeutic approaches to the treatment of dyslipidemia 2: LDL-C and Lp(a). J Lipid Atheroscler. 2023;12:37\u201346.","journal-title":"J Lipid Atheroscler"},{"key":"50_CR75","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.tig.2011.02.004","volume":"27","author":"SM Hammond","year":"2011","unstructured":"Hammond SM, Wood MJ. Genetic therapies for RNA mis-splicing diseases. Trends Genet. 2011;27:196\u2013205.","journal-title":"Trends Genet"},{"key":"50_CR76","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1126\/science.1236921","volume":"342","author":"J Jiang","year":"2013","unstructured":"Jiang J, Wakimoto H, Seidman JG, Seidman CE. Allele-specific silencing of mutant Myh6 transcripts in mice suppresses hypertrophic cardiomyopathy. Science. 2013;342:111\u20134.","journal-title":"Science"},{"key":"50_CR77","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/emmm.201202168","volume":"5","author":"C Gedicke-Hornung","year":"2013","unstructured":"Gedicke-Hornung C, Behrens-Gawlik V, Reischmann S, Geertz B, Stimpel D, Weinberger F, et al. Rescue of cardiomyopathy through U7snRNA-mediated exon skipping in Mybpc3-targeted knock-in mice. EMBO Mol Med. 2013;5:1128\u201345.","journal-title":"EMBO Mol Med"},{"key":"50_CR78","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.ymthe.2020.07.021","volume":"28","author":"YK Jeong","year":"2020","unstructured":"Jeong YK, Song B, Bae S. Current status and challenges of DNA base editing tools. Mol Ther. 2020;28:1938\u201352.","journal-title":"Mol Ther"},{"key":"50_CR79","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/s41434-023-00384-3","volume":"30","author":"J Nie","year":"2023","unstructured":"Nie J, Han Y, Jin Z, Hang W, Shu H, Wen Z, et al. Homology-directed repair of an MYBPC3 gene mutation in a rat model of hypertrophic cardiomyopathy. Gene Ther. 2023;30:520\u20137.","journal-title":"Gene Ther"},{"key":"50_CR80","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s44348-024-00009-2","volume":"32","author":"S Chang","year":"2024","unstructured":"Chang S, Kim HS, Jung MH, Kim M, Youn JC. Delayed onset of hypertrophic cardiomyopathy in a 61-year-old male patient with MYBPC3 mutation. J Cardiovasc Imaging. 2024;32:24.","journal-title":"J Cardiovasc Imaging"},{"key":"50_CR81","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1016\/j.jacc.2020.12.071","volume":"77","author":"C Semsarian","year":"2021","unstructured":"Semsarian C, Ingles J, Ross SB, Dunwoodie SL, Bagnall RD, Kovacic JC. Precision medicine in cardiovascular disease: genetics and impact on phenotypes: JACC Focus Seminar 1\/5. J Am Coll Cardiol. 2021;77:2517\u201330.","journal-title":"J Am Coll Cardiol"},{"key":"50_CR82","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1002\/ehf2.14803","volume":"11","author":"SY Lee","year":"2024","unstructured":"Lee SY, Kim HS, Jung MH, Chang S, Kim M, Youn JC, et al. Genetic predisposition in chemotherapy-induced cardiomyopathy in a 65-year-old female with metastatic breast cancer. ESC Heart Fail. 2024;11:2410\u20134.","journal-title":"ESC Heart Fail"},{"key":"50_CR83","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/s41569-021-00566-9","volume":"18","author":"CS Weldy","year":"2021","unstructured":"Weldy CS, Ashley EA. Towards precision medicine in heart failure. Nat Rev Cardiol. 2021;18:745\u201362.","journal-title":"Nat Rev Cardiol"},{"key":"50_CR84","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.jcmg.2017.07.016","volume":"10","author":"EJ Rowin","year":"2017","unstructured":"Rowin EJ, Maron BJ, Olivotto I, Maron MS. Role of exercise testing in hypertrophic cardiomyopathy. JACC Cardiovasc Imaging. 2017;10:1374\u201386.","journal-title":"JACC Cardiovasc Imaging"},{"key":"50_CR85","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/00000658-196108000-00003","volume":"154","author":"AG Morrow","year":"1961","unstructured":"Morrow AG, Brockenbrough EC. Surgical treatment of idiopathic hypertrophic subaortic stenosis: technic and hemodynamic results of subaortic ventriculomyotomy. Ann Surg. 1961;154:181\u20139.","journal-title":"Ann Surg"},{"key":"50_CR86","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jacc.2021.11.021","volume":"79","author":"BJ Maron","year":"2022","unstructured":"Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, et al. Management of hypertrophic cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2022;79:390\u2013414.","journal-title":"J Am Coll Cardiol"},{"key":"50_CR87","doi-asserted-by":"crossref","unstructured":"Morrow AG, Reitz BA, Epstein SE, Henry WL, Conkle DM, Itscoitz SB, et al. Operative treatment in hypertrophic subaortic stenosis. Techniques, and the results of pre and postoperative assessments in 83 patients. Circulation. 1975;52:88\u2013102.","DOI":"10.1161\/01.CIR.52.1.88"},{"key":"50_CR88","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/0003-4975(94)92268-3","volume":"58","author":"BJ Messmer","year":"1994","unstructured":"Messmer BJ. Extended myectomy for hypertrophic obstructive cardiomyopathy. Ann Thorac Surg. 1994;58:575\u20137.","journal-title":"Ann Thorac Surg"},{"key":"50_CR89","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/j.jtcvs.2018.11.148","volume":"157","author":"K Hodges","year":"2019","unstructured":"Hodges K, Rivas CG, Aguilera J, Borden R, Alashi A, Blackstone EH, et al. Surgical management of left ventricular outflow tract obstruction in a specialized hypertrophic obstructive cardiomyopathy center. J Thorac Cardiovasc Surg. 2019;157:2289\u201399.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"50_CR90","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.athoracsur.2020.05.182","volume":"111","author":"D Sun","year":"2021","unstructured":"Sun D, Schaff HV, Nishimura RA, Geske JB, Dearani JA, Ommen SR. Transapical septal myectomy for hypertrophic cardiomyopathy with midventricular obstruction. Ann Thorac Surg. 2021;111:836\u201344.","journal-title":"Ann Thorac Surg"},{"key":"50_CR91","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1016\/j.jtcvs.2017.10.054","volume":"155","author":"D Hang","year":"2018","unstructured":"Hang D, Schaff HV, Ommen SR, Dearani JA, Nishimura RA. Combined transaortic and transapical approach to septal myectomy in patients with complex hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg. 2018;155:2096\u2013102.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"50_CR92","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.athoracsur.2013.04.073","volume":"96","author":"MR Kunkala","year":"2013","unstructured":"Kunkala MR, Schaff HV, Nishimura RA, Abel MD, Sorajja P, Dearani JA, et al. Transapical approach to myectomy for midventricular obstruction in hypertrophic cardiomyopathy. Ann Thorac Surg. 2013;96:564\u201370.","journal-title":"Ann Thorac Surg"},{"key":"50_CR93","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/j.1540-8191.2012.01475.x","volume":"27","author":"SM Said","year":"2012","unstructured":"Said SM, Schaff HV, Abel MD, Dearani JA. Transapical approach for apical myectomy and relief of midventricular obstruction in hypertrophic cardiomyopathy. J Card Surg. 2012;27:443\u20138.","journal-title":"J Card Surg"},{"key":"50_CR94","unstructured":"McIntosh CL, Maron BJ, Cannon RO 3rd, Klues HG. Initial results of combined anterior mitral leaflet plication and ventricular septal myotomy-myectomy for relief of left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. Circulation. 1992;86(5 Suppl):II60\u20137."},{"key":"50_CR95","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/0735-1097(96)00103-9","volume":"28","author":"MJ Kofflard","year":"1996","unstructured":"Kofflard MJ, van Herwerden LA, Waldstein DJ, Ruygrok P, Boersma E, Taams MA, et al. Initial results of combined anterior mitral leaflet extension and myectomy in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 1996;28:197\u2013202.","journal-title":"J Am Coll Cardiol"},{"key":"50_CR96","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.jacc.2016.07.735","volume":"68","author":"JH Hong","year":"2016","unstructured":"Hong JH, Schaff HV, Nishimura RA, Abel MD, Dearani JA, Li Z, et al. Mitral regurgitation in patients with hypertrophic obstructive cardiomyopathy: implications for concomitant valve procedures. J Am Coll Cardiol. 2016;68:1497\u2013504.","journal-title":"J Am Coll Cardiol"},{"key":"50_CR97","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.amjcard.2019.09.029","volume":"125","author":"G Boll","year":"2020","unstructured":"Boll G, Rowin EJ, Maron BJ, Wang W, Rastegar H, Maron MS. Efficacy of combined Cox-Maze IV and ventricular septal myectomy for treatment of atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2020;125:120\u20136.","journal-title":"Am J Cardiol"},{"key":"50_CR98","doi-asserted-by":"crossref","unstructured":"Heric B, Lytle BW, Miller DP, Rosenkranz ER, Lever HM, Cosgrove DM. Surgical management of hypertrophic obstructive cardiomyopathy. Early and late results. J Thorac Cardiovasc Surg. 1995;110:195\u2013208.","DOI":"10.1016\/S0022-5223(05)80026-1"},{"key":"50_CR99","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jacc.2005.02.090","volume":"46","author":"SR Ommen","year":"2005","unstructured":"Ommen SR, Maron BJ, Olivotto I, Maron MS, Cecchi F, Betocchi S, et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;46:470\u20136.","journal-title":"J Am Coll Cardiol"},{"key":"50_CR100","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1161\/01.CIR.0000162460.36735.71","volume":"111","author":"A Woo","year":"2005","unstructured":"Woo A, Williams WG, Choi R, Wigle ED, Rozenblyum E, Fedwick K, et al. Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation. 2005;111:2033\u201341.","journal-title":"Circulation"},{"key":"50_CR101","doi-asserted-by":"publisher","first-page":"353","DOI":"10.21037\/acs.2017.07.07","volume":"6","author":"H Rastegar","year":"2017","unstructured":"Rastegar H, Boll G, Rowin EJ, Dolan N, Carroll C, Udelson JE, et al. Results of surgical septal myectomy for obstructive hypertrophic cardiomyopathy: the Tufts experience. Ann Cardiothorac Surg. 2017;6:353\u201363.","journal-title":"Ann Cardiothorac Surg"},{"key":"50_CR102","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/S0022-5223(96)70310-0","volume":"111","author":"RC Robbins","year":"1996","unstructured":"Robbins RC, Stinson EB. Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg. 1996;111:586\u201394.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"50_CR103","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1055\/s-2007-1013146","volume":"47","author":"HD Schulte","year":"1999","unstructured":"Schulte HD, Borisov K, Gams E, Gramsch-Zabel H, Losse B, Schwartzkopff B. Management of symptomatic hypertrophic obstructive cardiomyopathy: long-term results after surgical therapy. Thorac Cardiovasc Surg. 1999;47:213\u20138.","journal-title":"Thorac Cardiovasc Surg"},{"key":"50_CR104","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1016\/j.jacc.2011.08.040","volume":"58","author":"W Ball","year":"2011","unstructured":"Ball W, Ivanov J, Rakowski H, Wigle ED, Linghorne M, Ralph-Edwards A, et al. Long-term survival in patients with resting obstructive hypertrophic cardiomyopathy comparison of conservative versus invasive treatment. J Am Coll Cardiol. 2011;58:2313\u201321.","journal-title":"J Am Coll Cardiol"},{"key":"50_CR105","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1161\/CIRCULATIONAHA.112.000849","volume":"128","author":"MY Desai","year":"2013","unstructured":"Desai MY, Bhonsale A, Smedira NG, Naji P, Thamilarasan M, Lytle BW, et al. Predictors of long-term outcomes in symptomatic hypertrophic obstructive cardiomyopathy patients undergoing surgical relief of left ventricular outflow tract obstruction. Circulation. 2013;128:209\u201316.","journal-title":"Circulation"},{"key":"50_CR106","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.jchf.2014.06.012","volume":"2","author":"PA Vriesendorp","year":"2014","unstructured":"Vriesendorp PA, Liebregts M, Steggerda RC, Schinkel AF, Willems R, Ten Cate FJ, et al. Long-term outcomes after medical and invasive treatment in patients with hypertrophic cardiomyopathy. JACC Heart Fail. 2014;2:630\u20136.","journal-title":"JACC Heart Fail"},{"key":"50_CR107","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1093\/eurheartj\/ehm117","volume":"28","author":"CJ McLeod","year":"2007","unstructured":"McLeod CJ, Ommen SR, Ackerman MJ, Weivoda PL, Shen WK, Dearani JA, et al. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. Eur Heart J. 2007;28:2583\u20138.","journal-title":"Eur Heart J"},{"key":"50_CR108","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.echo.2007.11.006","volume":"21","author":"SC Menon","year":"2008","unstructured":"Menon SC, Ackerman MJ, Ommen SR, Cabalka AK, Hagler DJ, O\u2019Leary PW, et al. Impact of septal myectomy on left atrial volume and left ventricular diastolic filling patterns: an echocardiographic study of young patients with obstructive hypertrophic cardiomyopathy. J Am Soc Echocardiogr. 2008;21:684\u20138.","journal-title":"J Am Soc Echocardiogr"},{"key":"50_CR109","doi-asserted-by":"publisher","first-page":"364","DOI":"10.21037\/acs.2017.05.12","volume":"6","author":"RD Vanderlaan","year":"2017","unstructured":"Vanderlaan RD, Woo A, Ralph-Edwards A. Isolated septal myectomy for hypertrophic obstructive cardiomyopathy: an update on the Toronto General Hospital experience. Ann Cardiothorac Surg. 2017;6:364\u20138.","journal-title":"Ann Cardiothorac Surg"},{"key":"50_CR110","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/j.jacc.2015.06.1333","volume":"66","author":"BJ Maron","year":"2015","unstructured":"Maron BJ, Dearani JA, Ommen SR, Maron MS, Schaff HV, Nishimura RA, et al. Low operative mortality achieved with surgical septal myectomy: role of dedicated hypertrophic cardiomyopathy centers in the management of dynamic subaortic obstruction. J Am Coll Cardiol. 2015;66:1307\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"50_CR111","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.athoracsur.2007.07.063","volume":"85","author":"NG Smedira","year":"2008","unstructured":"Smedira NG, Lytle BW, Lever HM, Rajeswaran J, Krishnaswamy G, Kaple RK, et al. Current effectiveness and risks of isolated septal myectomy for hypertrophic obstructive cardiomyopathy. Ann Thorac Surg. 2008;85:127\u201333.","journal-title":"Ann Thorac Surg"},{"key":"50_CR112","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.athoracsur.2012.08.011","volume":"95","author":"SE Altarabsheh","year":"2013","unstructured":"Altarabsheh SE, Dearani JA, Burkhart HM, Schaff HV, Deo SV, Eidem BW, et al. Outcome of septal myectomy for obstructive hypertrophic cardiomyopathy in children and young adults. Ann Thorac Surg. 2013;95:663\u20139.","journal-title":"Ann Thorac Surg"},{"key":"50_CR113","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1093\/eurheartj\/ehs064","volume":"33","author":"A Iacovoni","year":"2012","unstructured":"Iacovoni A, Spirito P, Simon C, Iascone M, Di Dedda G, De Filippo P, et al. A contemporary European experience with surgical septal myectomy in hypertrophic cardiomyopathy. Eur Heart J. 2012;33:2080\u20137.","journal-title":"Eur Heart J"},{"key":"50_CR114","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.jacc.2019.05.053","volume":"74","author":"H Cui","year":"2019","unstructured":"Cui H, Schaff HV, Nishimura RA, Geske JB, Dearani JA, Lahr BD, et al. Conduction abnormalities and long-term mortality following septal myectomy in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2019;74:645\u201355.","journal-title":"J Am Coll Cardiol"},{"key":"50_CR115","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.amjcard.2014.07.075","volume":"114","author":"SS Panaich","year":"2014","unstructured":"Panaich SS, Badheka AO, Chothani A, Mehta K, Patel NJ, Deshmukh A, et al. Results of ventricular septal myectomy and hypertrophic cardiomyopathy (from Nationwide Inpatient Sample [1998-2010]). Am J Cardiol. 2014;114:1390\u20135.","journal-title":"Am J Cardiol"},{"key":"50_CR116","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.athoracsur.2005.03.108","volume":"80","author":"K Minakata","year":"2005","unstructured":"Minakata K, Dearani JA, Schaff HV, O\u2019Leary PW, Ommen SR, Danielson GK. Mechanisms for recurrent left ventricular outflow tract obstruction after septal myectomy for obstructive hypertrophic cardiomyopathy. Ann Thorac Surg. 2005;80:851\u20136.","journal-title":"Ann Thorac Surg"},{"key":"50_CR117","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.jtcvs.2014.05.028","volume":"148","author":"YH Cho","year":"2014","unstructured":"Cho YH, Quintana E, Schaff HV, Nishimura RA, Dearani JA, Abel MD, et al. Residual and recurrent gradients after septal myectomy for hypertrophic cardiomyopathy-mechanisms of obstruction and outcomes of reoperation. J Thorac Cardiovasc Surg. 2014;148:909\u201316.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"50_CR118","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1001\/jamacardio.2016.0252","volume":"1","author":"LK Kim","year":"2016","unstructured":"Kim LK, Swaminathan RV, Looser P, Minutello RM, Wong SC, Bergman G, et al. Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US Nationwide Inpatient Database, 2003\u20132011. JAMA Cardiol. 2016;1:324\u201332.","journal-title":"JAMA Cardiol"},{"key":"50_CR119","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1159\/000504215","volume":"145","author":"AR Polanco","year":"2020","unstructured":"Polanco AR, D\u2019Angelo A, Shea N, Yu SN, Chiang YP, Shimada Y, et al. Impact of septal myectomy volume on mitral-valve replacement rate in hypertrophic cardiomyopathy patients. Cardiology. 2020;145:161\u20137.","journal-title":"Cardiology"},{"key":"50_CR120","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.mayocp.2018.07.022","volume":"94","author":"KA Holst","year":"2019","unstructured":"Holst KA, Hanson KT, Ommen SR, Nishimura RA, Habermann EB, Schaff HV. Septal myectomy in hypertrophic cardiomyopathy: national outcomes of concomitant mitral surgery. Mayo Clin Proc. 2019;94:66\u201373.","journal-title":"Mayo Clin Proc"},{"key":"50_CR121","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.827860","volume":"9","author":"P Wei","year":"2022","unstructured":"Wei P, Liu J, Ma J, Liu Y, Tan T, Wu H, et al. Thoracoscopic trans-mitral septal myectomy for hypertrophic obstructive cardiomyopathy in the elderly. Front Cardiovasc Med. 2022;9: 827860.","journal-title":"Front Cardiovasc Med"},{"key":"50_CR122","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1016\/j.athoracsur.2021.10.030","volume":"114","author":"\u015e \u015eenay","year":"2022","unstructured":"\u015eenay \u015e, Bastopcu M, G\u00fcll\u00fc A\u00dc, Ko\u00e7yi\u011fit M, K\u0131l\u0131\u00e7 L, Alhan C. Robotic mitral valve surgery with intracardiac ultrasound-guided septal myectomy. Ann Thorac Surg. 2022;114:e59-61.","journal-title":"Ann Thorac Surg"},{"key":"50_CR123","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jacc.2023.05.052","volume":"82","author":"J Fang","year":"2023","unstructured":"Fang J, Liu Y, Zhu Y, Li R, Wang R, Wang DW, et al. First-in-human transapical beating-heart septal myectomy in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2023;82:575\u201386.","journal-title":"J Am Coll Cardiol"},{"key":"50_CR124","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1161\/CIRCULATIONAHA.115.015842","volume":"132","author":"DH Yang","year":"2015","unstructured":"Yang DH, Kang JW, Kim N, Song JK, Lee JW, Lim TH. Myocardial 3-dimensional printing for septal myectomy guidance in a patient with obstructive hypertrophic cardiomyopathy. Circulation. 2015;132:300\u20131.","journal-title":"Circulation"},{"key":"50_CR125","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.3348\/kjr.2020.1164","volume":"22","author":"W Kim","year":"2021","unstructured":"Kim W, Lim M, Jang YJ, Koo HJ, Kang JW, Jung SH, et al. Novel resectable myocardial model using hybrid three-dimensional printing and silicone molding for mock myectomy for apical hypertrophic cardiomyopathy. Korean J Radiol. 2021;22:1054\u201365.","journal-title":"Korean J Radiol"},{"key":"50_CR126","doi-asserted-by":"publisher","DOI":"10.1148\/rg.230050","volume":"44","author":"HJ Koo","year":"2024","unstructured":"Koo HJ, Lee SA, Jung SH, Kang JW, Yang DH. Tailored planning of surgical myectomy in obstructive hypertrophic cardiomyopathy. Radiographics. 2024;44: e230050.","journal-title":"Radiographics"},{"key":"50_CR127","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1161\/CIRCULATIONAHA.118.035484","volume":"138","author":"MS Maron","year":"2018","unstructured":"Maron MS, Spirito P, Maron BJ. Case for earlier surgical myectomy in patients with obstructive hypertrophic cardiomyopathy. Circulation. 2018;138:2076\u20138.","journal-title":"Circulation"},{"key":"50_CR128","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.016210","volume":"10","author":"A Alashi","year":"2021","unstructured":"Alashi A, Smedira NG, Hodges K, Popovic ZB, Thamilarasan M, Wierup P, et al. Outcomes in guideline-based class I indication versus earlier referral for surgical myectomy in hypertrophic obstructive cardiomyopathy. J Am Heart Assoc. 2021;10: e016210.","journal-title":"J Am Heart Assoc"},{"key":"50_CR129","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1093\/ehjci\/jew024","volume":"17","author":"KC Ong","year":"2016","unstructured":"Ong KC, Geske JB, Hebl VB, Nishimura RA, Schaff HV, Ackerman MJ, et al. Pulmonary hypertension is associated with worse survival in hypertrophic cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2016;17:604\u201310.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"50_CR130","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jcmg.2013.08.010","volume":"7","author":"MY Desai","year":"2014","unstructured":"Desai MY, Bhonsale A, Patel P, Naji P, Smedira NG, Thamilarasan M, et al. Exercise echocardiography in asymptomatic HCM: exercise capacity, and not LV outflow tract gradient predicts long-term outcomes. JACC Cardiovasc Imaging. 2014;7:26\u201336.","journal-title":"JACC Cardiovasc Imaging"},{"key":"50_CR131","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.athoracsur.2018.03.039","volume":"106","author":"A Nguyen","year":"2018","unstructured":"Nguyen A, Schaff HV, Nishimura RA, Dearani JA, Geske JB, Lahr BD, et al. Determinants of reverse remodeling of the left atrium after transaortic myectomy. Ann Thorac Surg. 2018;106:447\u201353.","journal-title":"Ann Thorac Surg"},{"key":"50_CR132","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jacc.2009.01.079","volume":"54","author":"P Sorajja","year":"2009","unstructured":"Sorajja P, Nishimura RA, Gersh BJ, Dearani JA, Hodge DO, Wiste HJ, et al. Outcome of mildly symptomatic or asymptomatic obstructive hypertrophic cardiomyopathy: a long-term follow-up study. J Am Coll Cardiol. 2009;54:234\u201341.","journal-title":"J Am Coll Cardiol"},{"key":"50_CR133","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S0140-6736(95)91267-3","volume":"346","author":"U Sigwart","year":"1995","unstructured":"Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet. 1995;346:211\u20134.","journal-title":"Lancet"},{"key":"50_CR134","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1016\/j.jacc.2011.06.073","volume":"58","author":"SF Nagueh","year":"2011","unstructured":"Nagueh SF, Groves BM, Schwartz L, Smith KM, Wang A, Bach RG, et al. Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy: a multicenter North American registry. J Am Coll Cardiol. 2011;58:2322\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"50_CR135","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1055\/s-0040-1709463","volume":"29","author":"VJ Ten","year":"2020","unstructured":"Ten VJ. tips and tricks for performing alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy. Int J Angiol. 2020;29:180\u20132.","journal-title":"Int J Angiol"},{"key":"50_CR136","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1016\/j.jacc.2018.09.064","volume":"72","author":"A Batzner","year":"2018","unstructured":"Batzner A, Pfeiffer B, Neugebauer A, Aicha D, Blank C, Seggewiss H. Survival after alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2018;72:3087\u201394.","journal-title":"J Am Coll Cardiol"},{"key":"50_CR137","doi-asserted-by":"crossref","unstructured":"Moya Mur JL, Salido Tahoces L, Mestre Barcel\u00f3 JL, Rodr\u00edguez Mu\u00f1oz D, Hern\u00e1ndez R, Fern\u00e1ndez-Golf\u00edn C, et al. Alcohol septal ablation in hypertrophic cardiomyopathy. 3D contrast echocardiography allows localization and quantification of the extension of intraprocedural vascular recruitment. Int J Cardiol. 2014;174:761\u20132.","DOI":"10.1016\/j.ijcard.2014.04.080"},{"key":"50_CR138","doi-asserted-by":"publisher","first-page":"411","DOI":"10.4244\/EIJ-D-18-00959","volume":"15","author":"F Pelliccia","year":"2019","unstructured":"Pelliccia F, Niccoli G, Gragnano F, Limongelli G, Moscarella E, And\u00f2 G, et al. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a contemporary reappraisal. EuroIntervention. 2019;15:411\u20137.","journal-title":"EuroIntervention"},{"key":"50_CR139","first-page":"462","volume":"47","author":"L Faber","year":"1999","unstructured":"Faber L, Seggewiss H, Ziemssen P, Gleichmann U. Intraprocedural myocardial contrast echocardiography as a routine procedure in percutaneous transluminal septal myocardial ablation: detection of threatening myocardial necrosis distant from the septal target area. Catheter Cardiovasc Interv. 1999;47:462\u20136.","journal-title":"Catheter Cardiovasc Interv"},{"key":"50_CR140","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.115.002675","volume":"9","author":"M Lu","year":"2016","unstructured":"Lu M, Du H, Gao Z, Song L, Cheng H, Zhang Y, et al. Predictors of outcome after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: an echocardiography and cardiovascular magnetic resonance imaging study. Circ Cardiovasc Interv. 2016;9: e002675.","journal-title":"Circ Cardiovasc Interv"},{"key":"50_CR141","first-page":"E58","volume":"81","author":"P Sorajja","year":"2013","unstructured":"Sorajja P, Binder J, Nishimura RA, Holmes DR Jr, Rihal CS, Gersh BJ, et al. Predictors of an optimal clinical outcome with alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Catheter Cardiovasc Interv. 2013;81:E58-67.","journal-title":"Catheter Cardiovasc Interv"},{"key":"50_CR142","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1093\/eurheartj\/ehv693","volume":"37","author":"J Veselka","year":"2016","unstructured":"Veselka J, Jensen MK, Liebregts M, Januska J, Krejci J, Bartel T, et al. Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry. Eur Heart J. 2016;37:1517\u201323.","journal-title":"Eur Heart J"},{"key":"50_CR143","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.jcin.2015.11.036","volume":"9","author":"M Liebregts","year":"2016","unstructured":"Liebregts M, Steggerda RC, Vriesendorp PA, van Velzen H, Schinkel AF, Willems R, et al. Long-term outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy in the young and the elderly. JACC Cardiovasc Interv. 2016;9:463\u20139.","journal-title":"JACC Cardiovasc Interv"},{"key":"50_CR144","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/j.amjcard.2005.12.040","volume":"97","author":"DM Yoerger","year":"2006","unstructured":"Yoerger DM, Picard MH, Palacios IF, Vlahakes GJ, Lowry PA, Fifer MA. Time course of pressure gradient response after first alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2006;97:1511\u20134.","journal-title":"Am J Cardiol"},{"key":"50_CR145","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1136\/heartjnl-2012-303339","volume":"99","author":"MK Jensen","year":"2013","unstructured":"Jensen MK, Prinz C, Horstkotte D, van Buuren F, Bitter T, Faber L, et al. Alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy: low incidence of sudden cardiac death and reduced risk profile. Heart. 2013;99:1012\u20137.","journal-title":"Heart"},{"key":"50_CR146","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1161\/CIRCULATIONAHA.111.076257","volume":"126","author":"P Sorajja","year":"2012","unstructured":"Sorajja P, Ommen SR, Holmes DR Jr, Dearani JA, Rihal CS, Gersh BJ, et al. Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation. 2012;126:2374\u201380.","journal-title":"Circulation"},{"key":"50_CR147","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jacc.2022.10.027","volume":"81","author":"A Mentias","year":"2023","unstructured":"Mentias A, Smedira NG, Krishnaswamy A, Reed GW, Ospina S, Thamilarasan M, et al. Survival after septal reduction in patients >65 years old with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2023;81:105\u201315.","journal-title":"J Am Coll Cardiol"},{"key":"50_CR148","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10840-018-0433-0","volume":"52","author":"P Fitzgerald","year":"2018","unstructured":"Fitzgerald P, Kusumoto F. The effects of septal myectomy and alcohol septal ablation for hypertrophic cardiomyopathy on the cardiac conduction system. J Interv Card Electrophysiol. 2018;52:403\u20138.","journal-title":"J Interv Card Electrophysiol"},{"key":"50_CR149","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1016\/j.ijcard.2006.04.057","volume":"113","author":"A Rigopoulos","year":"2006","unstructured":"Rigopoulos A, Sepp R, Palinkas A, Ungi I, Kremastinos DT, Seggewiss H. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: collateral vessel communication between septal branches. Int J Cardiol. 2006;113:e67\u20139.","journal-title":"Int J Cardiol"},{"key":"50_CR150","first-page":"231","volume":"63","author":"J Veselka","year":"2004","unstructured":"Veselka J, Proch\u00e1zkov\u00e1 S, Duchonov\u00e1 R, Bolomov\u00e1-Homolov\u00e1 I, P\u00e1len\u00edckov\u00e1 J, Tesar D, et al. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: lower alcohol dose reduces size of infarction and has comparable hemodynamic and clinical outcome. Catheter Cardiovasc Interv. 2004;63:231\u20135.","journal-title":"Catheter Cardiovasc Interv"},{"key":"50_CR151","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jacc.2006.08.055","volume":"49","author":"US Valeti","year":"2007","unstructured":"Valeti US, Nishimura RA, Holmes DR, Araoz PA, Glockner JF, Breen JF, et al. Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2007;49:350\u20137.","journal-title":"J Am Coll Cardiol"},{"key":"50_CR152","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.jchf.2014.07.008","volume":"2","author":"BJ Maron","year":"2014","unstructured":"Maron BJ, Nishimura RA. Revisiting arrhythmic risk after alcohol septal ablation: is the pendulum finally swinging\u2026back to myectomy? JACC Heart Fail. 2014;2:637\u201340.","journal-title":"JACC Heart Fail"},{"key":"50_CR153","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1161\/CIRCHEARTFAILURE.109.862359","volume":"3","author":"FJ ten Cate","year":"2010","unstructured":"ten Cate FJ, Soliman OI, Michels M, Theuns DA, de Jong PL, Geleijnse ML, et al. Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: a word of caution. Circ Heart Fail. 2010;3:362\u20139.","journal-title":"Circ Heart Fail"},{"key":"50_CR154","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.amjcard.2009.02.056","volume":"104","author":"PA Noseworthy","year":"2009","unstructured":"Noseworthy PA, Rosenberg MA, Fifer MA, Palacios IF, Lowry PA, Ruskin JN, et al. Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2009;104:128\u201332.","journal-title":"Am J Cardiol"},{"key":"50_CR155","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.hrthm.2020.08.013","volume":"18","author":"PA Bleszynski","year":"2021","unstructured":"Bleszynski PA, Goldenberg I, Fernandez G, Howell E, Younis A, Chen AY, et al. Risk of arrhythmic events after alcohol septal ablation for hypertrophic cardiomyopathy using continuous implantable cardiac monitoring. Heart Rhythm. 2021;18:50\u20136.","journal-title":"Heart Rhythm"},{"key":"50_CR156","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.119.008540","volume":"13","author":"B El-Sabawi","year":"2020","unstructured":"El-Sabawi B, Nishimura RA, Barsness GW, Cha YM, Geske JB, Eleid MF. Temporal occurrence of arrhythmic complications after alcohol septal ablation. Circ Cardiovasc Interv. 2020;13: e008540.","journal-title":"Circ Cardiovasc Interv"},{"key":"50_CR157","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1161\/CIRCULATIONAHA.114.011580","volume":"130","author":"BJ Maron","year":"2014","unstructured":"Maron BJ, Nishimura RA. Surgical septal myectomy versus alcohol septal ablation: assessing the status of the controversy in 2014. Circulation. 2014;130:1617\u201324.","journal-title":"Circulation"},{"key":"50_CR158","doi-asserted-by":"crossref","unstructured":"Olivotto I, Ommen SR, Maron MS, Cecchi F, Maron BJ. Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Will there ever be a randomized trial? J Am Coll Cardiol. 2007;50:831\u20134.","DOI":"10.1016\/j.jacc.2007.05.018"},{"key":"50_CR159","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jacc.2009.09.047","volume":"55","author":"S Agarwal","year":"2010","unstructured":"Agarwal S, Tuzcu EM, Desai MY, Smedira N, Lever HM, Lytle BW, et al. Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;55:823\u201334.","journal-title":"J Am Coll Cardiol"},{"key":"50_CR160","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.118.007673","volume":"12","author":"C Kimmelstiel","year":"2019","unstructured":"Kimmelstiel C, Zisa DC, Kuttab JS, Wells S, Udelson JE, Wessler BS, et al. Guideline-based referral for septal reduction therapy in obstructive hypertrophic cardiomyopathy is associated with excellent clinical outcomes. Circ Cardiovasc Interv. 2019;12: e007673.","journal-title":"Circ Cardiovasc Interv"},{"key":"50_CR161","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.jcin.2014.05.023","volume":"7","author":"RC Steggerda","year":"2014","unstructured":"Steggerda RC, Damman K, Balt JC, Liebregts M, ten Berg JM, van den Berg MP. Periprocedural complications and long-term outcome after alcohol septal ablation versus surgical myectomy in hypertrophic obstructive cardiomyopathy: a single-center experience. JACC Cardiovasc Interv. 2014;7:1227\u201334.","journal-title":"JACC Cardiovasc Interv"},{"key":"50_CR162","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.amjcard.2022.02.033","volume":"172","author":"C Bourque","year":"2022","unstructured":"Bourque C, R\u00e9ant P, Bernard A, Leroux L, Bonnet G, Pernot M, et al. Comparison of surgical ventricular septal reduction to alcohol septal ablation therapy in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2022;172:109\u201314.","journal-title":"Am J Cardiol"},{"key":"50_CR163","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/j.jacc.2022.02.032","volume":"79","author":"H Cui","year":"2022","unstructured":"Cui H, Schaff HV, Wang S, Lahr BD, Rowin EJ, Rastegar H, et al. Survival following alcohol septal ablation or septal myectomy for patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2022;79:1647\u201355.","journal-title":"J Am Coll Cardiol"},{"key":"50_CR164","doi-asserted-by":"crossref","unstructured":"Yokoyama Y, Shimoda T, Shimada YJ, Shimamura J, Akita K, Yasuda R, et al. Alcohol septal ablation versus surgical septal myectomy of obstructive hypertrophic cardiomyopathy: systematic review and meta-analysis. Eur J Cardiothorac Surg. 2023;63:ezad043.","DOI":"10.1093\/ejcts\/ezad043"},{"key":"50_CR165","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jtcvs.2018.08.062","volume":"157","author":"A Nguyen","year":"2019","unstructured":"Nguyen A, Schaff HV, Hang D, Nishimura RA, Geske JB, Dearani JA, et al. Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy: a propensity score-matched cohort. J Thorac Cardiovasc Surg. 2019;157:306\u201315.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"50_CR166","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1016\/j.jacc.2004.04.063","volume":"44","author":"BJ Maron","year":"2004","unstructured":"Maron BJ, Dearani JA, Ommen SR, Maron MS, Schaff HV, Gersh BJ, et al. The case for surgery in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;44:2044\u201353.","journal-title":"J Am Coll Cardiol"},{"key":"50_CR167","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jtcvs.2015.03.044","volume":"150","author":"E Quintana","year":"2015","unstructured":"Quintana E, Sabate-Rotes A, Maleszewski JJ, Ommen SR, Nishimura RA, Dearani JA, et al. Septal myectomy after failed alcohol ablation: does previous percutaneous intervention compromise outcomes of myectomy? J Thorac Cardiovasc Surg. 2015;150:159\u201367.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"50_CR168","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1093\/eurheartj\/ehx370","volume":"38","author":"JB Chambers","year":"2017","unstructured":"Chambers JB, Prendergast B, Iung B, Rosenhek R, Zamorano JL, Pi\u00e9rard LA, et al. Standards defining a \u2018Heart Valve Centre\u2019: ESC Working Group on Valvular Heart Disease and European Association for Cardiothoracic Surgery Viewpoint. Eur Heart J. 2017;38:2177\u201383.","journal-title":"Eur Heart J"},{"key":"50_CR169","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ijcard.2020.01.021","volume":"304","author":"F Pelliccia","year":"2020","unstructured":"Pelliccia F, Alfieri O, Calabr\u00f2 P, Cecchi F, Ferrazzi P, Gragnano F, et al. Multidisciplinary evaluation and management of obstructive hypertrophic cardiomyopathy in 2020: towards the HCM Heart Team. Int J Cardiol. 2020;304:86\u201392.","journal-title":"Int J Cardiol"},{"key":"50_CR170","first-page":"971","volume":"88","author":"I Guerrero","year":"2016","unstructured":"Guerrero I, Dhoble A, Fasulo M, Denktas AE, Sami S, Choi S, et al. Safety and efficacy of coil embolization of the septal perforator for septal ablation in patients with hypertrophic obstructive cardiomyopathy. Catheter Cardiovasc Interv. 2016;88:971\u20137.","journal-title":"Catheter Cardiovasc Interv"},{"key":"50_CR171","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1093\/eurheartj\/ehm632","volume":"29","author":"E Durand","year":"2008","unstructured":"Durand E, Mousseaux E, Coste P, Pilli\u00e8re R, Dubourg O, Trinquart L, et al. Non-surgical septal myocardial reduction by coil embolization for hypertrophic obstructive cardiomyopathy: early and 6 months follow-up. Eur Heart J. 2008;29:348\u201355.","journal-title":"Eur Heart J"},{"key":"50_CR172","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1540-8183.2010.00605.x","volume":"24","author":"A Oto","year":"2011","unstructured":"Oto A, Aytemir K, Okutucu S, Kaya EB, Deniz A, Cil B, et al. Cyanoacrylate for septal ablation in hypertrophic cardiomyopathy. J Interv Cardiol. 2011;24:77\u201384.","journal-title":"J Interv Cardiol"},{"key":"50_CR173","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1583\/03-1171MR.1","volume":"11","author":"CM Gross","year":"2004","unstructured":"Gross CM, Schulz-Menger J, Kr\u00e4mer J, Siegel I, Pilz B, Waigand J, et al. Percutaneous transluminal septal artery ablation using polyvinyl alcohol foam particles for septal hypertrophy in patients with hypertrophic obstructive cardiomyopathy: acute and 3-year outcomes. J Endovasc Ther. 2004;11:705\u201311.","journal-title":"J Endovasc Ther"},{"key":"50_CR174","first-page":"231","volume":"69","author":"GA Llamas-Esper\u00f3n","year":"2007","unstructured":"Llamas-Esper\u00f3n GA, Sandoval-Navarrete S. Percutaneous septal ablation with absorbable gelatin sponge in hypertrophic obstructive cardiomyopathy. Catheter Cardiovasc Interv. 2007;69:231\u20135.","journal-title":"Catheter Cardiovasc Interv"},{"key":"50_CR175","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jacc.2010.07.055","volume":"57","author":"T Lawrenz","year":"2011","unstructured":"Lawrenz T, Borchert B, Leuner C, Bartelsmeier M, Reinhardt J, Strunk-Mueller C, et al. Endocardial radiofrequency ablation for hypertrophic obstructive cardiomyopathy: acute results and 6 months\u2019 follow-up in 19 patients. J Am Coll Cardiol. 2011;57:572\u20136.","journal-title":"J Am Coll Cardiol"},{"key":"50_CR176","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1016\/j.jacc.2011.09.020","volume":"58","author":"N Sreeram","year":"2011","unstructured":"Sreeram N, Emmel M, de Giovanni JV. Percutaneous radiofrequency septal reduction for hypertrophic obstructive cardiomyopathy in children. J Am Coll Cardiol. 2011;58:2501\u201310.","journal-title":"J Am Coll Cardiol"},{"key":"50_CR177","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1016\/j.hrthm.2016.04.018","volume":"13","author":"K Crossen","year":"2016","unstructured":"Crossen K, Jones M, Erikson C. Radiofrequency septal reduction in symptomatic hypertrophic obstructive cardiomyopathy. Heart Rhythm. 2016;13:1885\u201390.","journal-title":"Heart Rhythm"},{"key":"50_CR178","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.ihj.2016.02.007","volume":"68","author":"AB Shelke","year":"2016","unstructured":"Shelke AB, Menon R, Kapadiya A, Yalagudri S, Saggu D, Nair S, et al. A novel approach in the use of radiofrequency catheter ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy. Indian Heart J. 2016;68:618\u201323.","journal-title":"Indian Heart J"},{"key":"50_CR179","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/europace\/euv302","volume":"18","author":"RM Cooper","year":"2016","unstructured":"Cooper RM, Shahzad A, Hasleton J, Digiovanni J, Hall MC, Todd DM, et al. Radiofrequency ablation of the interventricular septum to treat outflow tract gradients in hypertrophic obstructive cardiomyopathy: a novel use of CARTOSound\u00ae technology to guide ablation. Europace. 2016;18:113\u201320.","journal-title":"Europace"},{"key":"50_CR180","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.743044","volume":"8","author":"Q Liu","year":"2021","unstructured":"Liu Q, Qiu H, Jiang R, Tang X, Guo W, Zhou K, et al. Selective interventricular septal radiofrequency ablation in patients with hypertrophic obstructive cardiomyopathy: who can benefit? Front Cardiovasc Med. 2021;8: 743044.","journal-title":"Front Cardiovasc Med"},{"key":"50_CR181","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.21037\/atm-21-2783","volume":"9","author":"L Kong","year":"2021","unstructured":"Kong L, Zhao Y, Pan H, Ma J, Qian J, Ge J. A modified endocardial radiofrequency ablation approach for hypertrophic obstructive cardiomyopathy guided by transthoracic echocardiography: a case series. Ann Transl Med. 2021;9:1006.","journal-title":"Ann Transl Med"},{"key":"50_CR182","doi-asserted-by":"crossref","unstructured":"Jiang T, Huang B, Huo S, Mageta LM, Guo J, Lv J, et al. Endocardial radiofrequency ablation vs. septal myectomy in patients with hypertrophic obstructive cardiomyopathy: a systematic review and meta-analysis. Front Surg. 2022;9:859205.","DOI":"10.3389\/fsurg.2022.859205"},{"key":"50_CR183","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/jamacardio.2022.0259","volume":"7","author":"M Zhou","year":"2022","unstructured":"Zhou M, Ta S, Hahn RT, Hsi DH, Leon MB, Hu R, et al. Percutaneous intramyocardial septal radiofrequency ablation in patients with drug-refractory hypertrophic obstructive cardiomyopathy. JAMA Cardiol. 2022;7:529\u201338.","journal-title":"JAMA Cardiol"}],"container-title":["Journal of Cardiovascular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s44348-025-00050-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s44348-025-00050-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s44348-025-00050-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T21:04:20Z","timestamp":1758747860000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcvi.biomedcentral.com\/articles\/10.1186\/s44348-025-00050-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":183,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["50"],"URL":"https:\/\/doi.org\/10.1186\/s44348-025-00050-9","relation":{},"ISSN":["2586-7210","2586-7296"],"issn-type":[{"value":"2586-7210","type":"print"},{"value":"2586-7296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,24]]},"assertion":[{"value":"20 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This review article does not contain any studies with human participants and thus does not require approval from our institutional review board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}